Early clinical experience with ⁶⁸Ga-Trivehexin PET/CT in parathyroid adenomas: a proof-of- concept imaging study.
68Ga-Trivehexin PET/CT was positive in more parathyroid adenoma cases than Sestamibi
Early clinical experience with ⁶⁸Ga-Trivehexin PET/CT in parathyroid adenomas: a proof-of- concept imaging study.
The success of surgical treatment in Primary Hyperparathyroidism (Primary Hyperparathyroidism) depends on the accurate localization of the parathyroid adenoma.
This proof-of-concept study aimed to evaluate the feasibility and potential diagnostic contribution of ⁶⁸Ga-Trivehexin PET/CT in detecting parathyroid adenoma in patients with Primary Hyperparathyroidism.
This single-center, prospective proof-of-concept study included 28 patients who had a biochemical diagnosis of Primary Hyperparathyroidism.
A significant proportion of cases with negative ⁹⁹ᵐTc- Sestamibi scintigraphy showed positive lesions with ⁶⁸Ga-Trivehexin PET/CT.
Statistically significant, moderate agreement levels were detected in all patients between ⁹⁹ᵐTc-Sestamibi scintigraphy and ⁶⁸Ga-Trivehexin PET/CT (kappa = 0.430; p = 0.013).
A moderate level of agreement was observed between the two methods in patients with histopathologically confirmed parathyroid adenoma (kappa = 0.429; p = 0.070).
The results of this proof-of-concept study imply that ⁶⁸Ga-Trivehexin PET/CT may be a feasible and promising imaging method for localizing parathyroid adenomas in patients with primary hyperparathyroidism.
It may offer potential contributions as a complementary diagnostic tool, particularly in selected cases where conventional imaging methods are limited. Further large, multicenter studies are needed to confirm these findings.